Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00116519
Status:
COMPLETED
Last Update Posted:
2007-01-26
First Post:
2005-06-29
Brief Title:
A Study in People With Abnormal Fat Levels in the Blood
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
PPAR Alpha A Phase 2 Dose-Finding and Safety Study for Atherogenic Dyslipidemia by Eli Lilly
Status:
COMPLETED
Status Verified Date:
2007-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purposes of this study are to determine
The safety of the study medication and any side effects that might be associated with it
Whether the study medication can help patients with low levels of good cholesterol HDL-C and high blood fats or triglycerides TG
How much of the study medication should be given to patients
How the study medication compares to fenofibrate Lofibra a drug used for people with low levels of HDL-C and high levels of TG
The safety of the study medication and any side effects that might be associated with it
Whether the study medication can help patients with low levels of good cholesterol HDL-C and high blood fats or triglycerides TG
How much of the study medication should be given to patients
How the study medication compares to fenofibrate Lofibra a drug used for people with low levels of HDL-C and high levels of TG
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H8D-MC-EMBB | None | None | None |